Skip to content
10-Q

Quarterly Report

Kezar Life Sciences, Inc.

0001628280-26-033104

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 7.39M sh
Shares Diluted Q1 2026 · Mar 31, 2026 7.34M sh
Shares Diluted Q1 2026 · Mar 31, 2025 7.31M sh
Dividends Paid Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $8K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$7.45M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$17.19M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $66.23M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $71.88M
Stockholders Equity Q1 2026 · Mar 31, 2026 $65.24M
Stockholders Equity Q1 2026 · Dec 31, 2025 $70.07M
Stockholders Equity Q1 2026 · Mar 31, 2025 $103.07M
Stockholders Equity Q1 2026 · Dec 31, 2024 $116.92M
Current Liabilities Q1 2026 · Mar 31, 2026 $2.76M
Current Liabilities Q1 2026 · Dec 31, 2025 $6.57M
Total Liabilities Q1 2026 · Mar 31, 2026 $2.76M
Total Liabilities Q1 2026 · Dec 31, 2025 $6.57M
Current Assets Q1 2026 · Mar 31, 2026 $67.56M
Current Assets Q1 2026 · Dec 31, 2025 $75.73M
Total Assets Q1 2026 · Mar 31, 2026 $68M
Total Assets Q1 2026 · Dec 31, 2025 $76.65M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.78
Eps Diluted Q1 2026 · Mar 31, 2025 −$2.27
Eps Basic Q1 2026 · Mar 31, 2026 −$0.78
Eps Basic Q1 2026 · Mar 31, 2025 −$2.27
Sga Expense Q1 2026 · Mar 31, 2026 $5.21M
Sga Expense Q1 2026 · Mar 31, 2025 $5.45M
Rd Expense Q1 2026 · Mar 31, 2026 $1.55M
Rd Expense Q1 2026 · Mar 31, 2025 $12.18M
Net Income Q1 2026 · Mar 31, 2026 −$5.76M
Net Income Q1 2026 · Mar 31, 2025 −$16.56M
Operating Income Q1 2026 · Mar 31, 2026 −$7.37M
Operating Income Q1 2026 · Mar 31, 2025 −$17.63M